Protein kinase inhibitor

Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS

Retrieved on: 
Friday, May 10, 2019
Tyrosine kinases, Peripheral membrane proteins, Bruton's tyrosine kinase, Protein kinase inhibitor, Tyrosine-kinase inhibitor, BTK, Tyrosine hydroxylase

Evobrutinib is the first oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor to show clinical proof of concept in RMS.

Key Points: 
  • Evobrutinib is the first oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor to show clinical proof of concept in RMS.
  • "As a leader in autoimmune diseases and MS weare proud of this in-house discovery at EMD Serono.
  • We look forward to continuing to investigate the potential of evobrutinib as we continue to address unmet patient needs in MS care."
  • "Evobrutinib is the first Bruton's tyrosine kinase inhibitor to demonstrate clinical proof of concept in multiple sclerosis.

VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, April 3, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Chemical compounds, Organic compounds, Aromatic compounds, Quinazolines, Lung cancer, Chloroarenes, Amines, Gefitinib, Morpholines, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Protein kinase inhibitor

A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).

Key Points: 
  • A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).
  • VIZIMPRO is approved in the EU for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
  • A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).
  • 4 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, March 29, 2019
Medicine, Clinical medicine, Cancer, RTT, Cancer treatments, Antineoplastic drugs, Everolimus, Eisai, Protein kinase inhibitor, Sorafenib

Hepatotoxicity.Across clinical studies enrolling 1,327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients.

Key Points: 
  • Hepatotoxicity.Across clinical studies enrolling 1,327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients.
  • In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimustreated patients (10% grade 3).
  • The LEAP clinical program also includes a new basket trial targeting six additional cancer types (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma and ovarian cancer).
  • Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide.

Selvita to Host Conference Call and Webcast on Thursday, March 28

Retrieved on: 
Thursday, March 21, 2019
Enzymes, Cancer, CD135, Acute myeloid leukemia, Oncology, Protein kinase inhibitor, Menarini, Tyrosine kinase inhibitors, Gilteritinib

Management will host a live video webcast at 10:00 a.m. CET/5:00 a.m. EST (Polish language).

Key Points: 
  • Management will host a live video webcast at 10:00 a.m. CET/5:00 a.m. EST (Polish language).
  • Selvita will also host a press conference for investors and media in Warsaw, Poland.
  • Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division.
  • SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia.

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

Retrieved on: 
Friday, February 15, 2019
Health, Biotechnology, Oncology, Research, FDA, Science, Chemical compounds, Enzymes, Branches of biology, Chronic myeloid leukemia, Tyrosine kinases, Chronic myelogenous leukemia, Leukemia, Philadelphia chromosome, Pyrimidines, ABL, Tyrosine-kinase inhibitor, Protein kinase inhibitor

Used together, Bio-Rads system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).

Key Points: 
  • Used together, Bio-Rads system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
  • The QXDx AutoDG ddPCR System and QXDx BCR-ABL %IS Kit represent the first-ever digital PCR solution that can monitor and directly quantitate the molecular response of patients with chronic myeloid leukemia under tyrosine kinase inhibitor therapy.
  • CML is a cancer of white blood cells that is characterized by a fusion of the BCR and ABL genes.
  • Tyrosine kinase inhibitor (TKI) therapy has transformed CML into a manageable chronic disease for many patients.

IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board

Retrieved on: 
Wednesday, February 13, 2019
Chemical compounds, Organic compounds, Chemistry, Cancer treatments, Chloroarenes, Epidermal growth factor receptor, Oncogenes, Onyx Pharmaceuticals, Sorafenib, Chiron Corporation, Protein kinase inhibitor

Prior to joining UCSF, Frank was Founder and Chief Scientific Officer at Onyx Pharmaceuticals, building on his earlier research and leadership experiences at Cetus and Chiron.

Key Points: 
  • Prior to joining UCSF, Frank was Founder and Chief Scientific Officer at Onyx Pharmaceuticals, building on his earlier research and leadership experiences at Cetus and Chiron.
  • At Onyx, heinitiated and led drug discovery efforts that led to the approval of Sorafenib for treatment of renal cell cancer and liver cancer.
  • Seller's seminal work in the identification of EGFR mutations in lung cancer led to life-saving EGFR inhibitors as standard-of-care for lung cancer patients.
  • "We are thrilled to have them join our Scientific Advisory board and look forward to their contributions to IDEAYA across our pipeline of precision medicine programs."

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

Retrieved on: 
Tuesday, February 5, 2019
Otsuka Pharmaceutical, Taiho Pharmaceutical, Tyrosine kinase receptors, Lung cancer, Taiho, Tyrosine-kinase inhibitor, Protein kinase inhibitor, Epidermal growth factor receptor, Non-small-cell lung carcinoma

TOKYO and CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho Pharmaceutical.

Key Points: 
  • TOKYO and CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho Pharmaceutical.
  • Taiho Pharmaceutical will receive an upfront payment, regulatory and sales milestones, as well as royalties based on net sales.
  • Taiho Ventures, LLC, a strategic corporate venture arm of Taiho Pharmaceutical, alongside Cullinan Oncology, will provide funding for Cullinan Pearl's Series A.
  • We are pleased to partner with Cullinan Oncology and its experienced management team in bringing this novel treatment to NSCLC patients," said Teruhiro Utsugi, Managing Director of Taiho Pharmaceutical.

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

Retrieved on: 
Tuesday, February 5, 2019
Otsuka Pharmaceutical, Taiho Pharmaceutical, Tyrosine kinase receptors, Lung cancer, Taiho, Tyrosine-kinase inhibitor, Protein kinase inhibitor, Epidermal growth factor receptor, Non-small-cell lung carcinoma

TOKYO and CAMBRIDGE, Massachusetts, Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho Pharmaceutical.

Key Points: 
  • TOKYO and CAMBRIDGE, Massachusetts, Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho Pharmaceutical.
  • Taiho Pharmaceutical will receive an upfront payment, regulatory and sales milestones, as well as royalties based on net sales.
  • Taiho Ventures, LLC, a strategic corporate venture arm of Taiho Pharmaceutical, alongside Cullinan Oncology, will provide funding for Cullinan Pearl's Series A.
  • We are pleased to partner with Cullinan Oncology and its experienced management team in bringing this novel treatment to NSCLC patients," said Teruhiro Utsugi, Managing Director of Taiho Pharmaceutical.

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Retrieved on: 
Friday, February 1, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Other Health, Research, Other Science, Science, General Health, Chemical compounds, Organic compounds, Lung cancer, Chemistry, Quinazolines, Tyrosine kinase receptors, Tyrosine kinase inhibitors, Amines, Protein kinase inhibitor, Epidermal growth factor receptor, Non-small-cell lung carcinoma, T790M

Patients with EGFR-mutated non-small cell lung cancer, a disease that is associated with low overall survival rates, are in need of more treatment options.

Key Points: 
  • Patients with EGFR-mutated non-small cell lung cancer, a disease that is associated with low overall survival rates, are in need of more treatment options.
  • Vizimpro is an oral, once-daily, irreversible pan-human epidermal growth factor receptor kinase inhibitor for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
  • In 2012, Pfizer and SFJ Pharmaceuticals entered into a collaborative development agreement to conduct ARCHER 1050 across multiple sites.
  • 2 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Global Tyrosine Kinase Inhibitors Market by Product, Application, Distribution Channel and Geography - Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 31, 2019
Health, Oncology, Pharmaceutical, Business process, Market analysis, Market research, Tyrosine kinase, Tyrosine-kinase inhibitor, Protein kinase inhibitor, Trend, Tyrosine kinase receptors, Indazoles, Tyrosine kinase inhibitors

The "Global Tyrosine Kinase Inhibitors Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Tyrosine Kinase Inhibitors Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Tyrosine Kinase Inhibitors Market is poised to grow strong during the forecast period 2017 to 2027.
  • Some of the prominent trends that the market is witnessing include rising awareness about cancer diagnosis, increasing disease incidences and technological developments among high-quality products.
  • Key market trends across the business segments, regions and countries
    Market Dynamics such as Drivers, Restraints, Opportunities and other trends